Oxytocin and cholecystokinin correlates with metabolic syndrome’s atherogenecity and adiposity indices

OBJECTIVES: Our study aimed to investigate the correlation between plasma oxytocin (OXT) and cholecystokinin (CCK) as well as conicity index (CI), waist circumference (WC), waist circumference to hip circumference (WHR) ratio, red cell distribution width (RDW_CV%), mean platelet volume (MPV; fL) and TG\HDL-C ratio in metabolic syndrome (MetS) and Type-2 diabetes mellitus (T2DM) patients. METHODS: In a cross-sectional design, 30 normoglycemic lean subjects (control), 30 nondiabetic MetS and 29 MetS-Pre/T2DM subjects were enrolled. Plasma OXT and CCK were measured by colorimetric-enzymatic assay and expressed as median (interquartile range). RESULTS: CCK plasma levels (pmol\L) lacked pronounced discrepancy in nondiabetic MetS and MetS-pre/T2DM groups vs. lean –healthy controls (9.67 (7.14 – 13.7) and 6.73 (5.06 – 7.68) vs. 5.2 (2.86 – 7.56); p= 0.129 and 0.708, respectively). OXT plasma concentrations (pg/mL) in both nondiabetic MetS and MetS-pre/T2DM groups were markedly (p<0.05) lower vs. controls’ (both 1975.4 (1522.25-3191.15) and 1403(1033.95-2567.3) vs. 4176.6 (2407.13-5243.3) but no inter-MetS groups variations in OXT levels were detected. In addition, the levels of following parameters and indices were substantially (p<0.05) elevated in both MetS and MetS-pre/T2DM groups when compared to healthy-lean controls; (WC; cm) (102(93-110) and(100(96-107) vs.(79(69-85)), WHR (0.91(0.88-0.93) and 0.9(0.87-0.92) vs. 0.82(0.75-0.91)), CI (1.15(1.08-1.22) and (1.15(1.06-1.18) vs. (0.97(0.87-1.05)), (RDW; CV%) (13.3(12.5-14) and 13.6(12.93-14.6) vs. 13.1(12.2-13.7)), TG\HDL-C ratio(5.105(3.79-6.75) and (4.68(2.16-6.55) vs. 1.31(0.94-1.97)), while (MPV;fL) was exceptionally higher for MetS-pre/T2DM group (but not for MetS group; p>0.05) when compared to control group (10.35(9.08-11.03), vs. 9.3(8.55-9.9)). CONCLUSIONS: in nondiabetic MetS and MetS-pre\T2DM patients; OXT circulating concentrations (unlike CCK) were substantially decreased vs. healthy-lean controls.